A clinical-stage biotechnology company developing immune-modulating therapies aimed at treating autoimmune and inflammatory diseases. Its lead program, MIS416, has been studied as a potential treatment for progressive multiple sclerosis by targeting innate immune pathways. Investors have followed th...
1 member of Congress has disclosed 1 trade in Innate Immunotherapeutics Ltd (IILTF), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-06-25 | Chris Collins | sell | $15K – $50K |